Skip to main content
Signal8

Trevena, Inc. (TRVN)

Sector: Biotechnology

Industry: Biotechnology

Trevena, Inc. logo

Trevena, Inc.

OTC:TRVNHealthcare
$0.0005
CLOSED
Mkt Cap$432
EV-
Float810K
O/S864K
VOL977 sh
$ Vol$0
RVOL2.18×
Inst Own0.0%
SI0.4%
Net Cash/Sh-
Dilution
Trevena, Inc. logoOTC:TRVNClosed$0.0005
Historical Data
DateOpenHighLowCloseVolume
Nov 13, 20260.00050.00050.00050.0005977
Nov 10, 20260.00040.00040.00040.0004117
Oct 26, 20260.01110.01110.01110.0111254
Oct 16, 20260.00040.00050.00040.00054,129
Oct 12, 20260.06600.06600.06600.0660833
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
9
HOLD
5
SELL
0
TOTAL14
Insider Trades
InsiderTypeShares
Bourdow Carrie L. profile photoBourdow Carrie L.Automatic Sell1.1K
Bourdow Carrie L. profile photoBourdow Carrie L.Automatic Sell285
Bourdow Carrie L. profile photoBourdow Carrie L.Automatic Sell285
Demitrack Mark profile photoDemitrack MarkAutomatic Sell20
Demitrack Mark profile photoDemitrack MarkAutomatic Sell45
Demitrack Mark profile photoDemitrack MarkAutomatic Sell144
Shareholders
0.0%
Institutional
(1)
6.2%
Insiderⓘ
(5)
11.0%
5%+ Owners
(1)
82.8%
Unattributed (incl. retail)ⓘ
Institutional0.0%
Insider6.2%
5%+ Beneficial11.0%
Unattributed (incl. retail)82.8%
Sources: 13F, Form 4, 13D/13GO/S: 863.8K · date not recorded
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Key Metrics
Market Cap$432
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.00%

based on 863,788 shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateOct 8, 2024
Shares Outstanding863,788
Authorized Shares
Float810,178
52-Week Range
$0.0003$0.0400
$0.0005(1st percentile)
Volume
Average Daily Volume449
977 today vs 449 avg(+118%)

30d Avg

449

60d Avg

707

90d Avg

778

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Trevena, Inc. (OTC: TRVN) traded at $0.0005 on Nov 13, 2026. 52-week range: $0.0003 to $0.0400. The company is in the Healthcare sector (Biotechnology).